AIM
BMRN icon

ARK Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ARK Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,228
Closed -$167K – 262
2022
Q2 		$167K Sell
2,228
-106
-5% -$8.44K ﹤0.01% 270
2022
Q1 		$180K Buy
+2,334
New +$195K ﹤0.01% 292
2017
Q1 		– Sell
-960
Closed -$80K – 106
2016
Q4 		$80K Buy
+960
New +$82.6K 0.03% 91

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ARK Investment Management's BMRN Position: Q3 2022 in Review

ARK Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 2,228 shares — an estimated $167K sold.

ARK Investment Management first reported a position in BMRN in Q4 2016 and held it in 3 quarters. The position peaked at $180K in Q1 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • ARK Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • ARK Investment Management sold 2,228 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $167K.
  • ARK Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • ARK Investment Management's BioMarin Pharmaceuticals position peaked at $180K in Q1 2022.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on ARK Investment Management's 13F filing for Q3 2022, filed 17 Oct 2022.